Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chromadex Corp CDXC

Technology Scientific & Technical Instruments
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished... see more

Recent & Breaking News (NDAQ:CDXC)

ChromaDex Announces Second Human Clinical Trial

Accesswire May 21, 2014

ChromaDex® CEO to Present at 15th Annual B. Riley Conference on May 19th at 9:30 am PDT / 12:30 pm EDT

PR Newswire May 14, 2014

ChromaDex Initiates Second Human Clinical Study for its Caffeine Ingredient, PURENERGY®

PR Newswire May 13, 2014

ChromaDex® Reports 32% Increase in First Quarter Revenue as Ingredient Sales Grow 97%

PR Newswire May 8, 2014

ChromaDex Signs Material Transfer Agreement With Wageningen University for NIAGEN(TM) Research

PR Newswire May 5, 2014

UM Technology Management Division and Research Partners Land National Award

PR Newswire April 23, 2014

ChromaDex Provides Update on $62 Million Ingredient Agreement with Network Marketing Company 5LINX®

PR Newswire April 23, 2014

ChromaDex CEO, Frank Jaksch, to Speak at 13th Annual Oxford International Conference on the Science of Botanicals

PR Newswire April 16, 2014

ChromaDex Signs Material Transfer Agreement With University of Copenhagen for NIAGEN(TM) Nicotinamide Riboside Research

PR Newswire April 15, 2014

ChromaDex Signs Collaboration Research Agreement with Brazilian Research Institute

PR Newswire April 7, 2014

Thorne Research Introduces a New Product, NiaCel(TM), Featuring NIAGEN(TM), To Support Healthy Aging

PR Newswire April 2, 2014

ChromaDex® Reports 2013 Full-Year Results

PR Newswire March 27, 2014

ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN(TM) Research

PR Newswire March 12, 2014

ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT

PR Newswire March 6, 2014

RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg

GlobeNewswire February 27, 2014

RedChip Emerging Growth Showcase on Jan. 22-23 Features Exclusive Interview With OPKO CEO Dr. Phil Frost

Globe Newswire January 17, 2014

ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST

PR Newswire January 17, 2014

ChromaDex CEO Frank Jaksch Clear Channel Business Talk Radio Interview ReCap DFW 1190AM

Marketwired January 10, 2014

ChromaDex CEO Frank Jaksch to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM

Marketwired January 6, 2014

ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®

PR Newswire January 6, 2014